The immune response is a dynamic multistep process with a complex system regulation. Identification of predictive biomarkers is therefore challenging. Deep investigation of an exceptional responder to pembrolizumab in ovarian cancer identifies a new mechanism of response and highlights the interest of individualized medicine strategy. Clin Cancer Res; 24(14); 3233-5. Â©2018 AACRSee related article by Bellone et al., p. 3282.

https://www.ncbi.nlm.nih.gov/pubmed/29581132